Document is current

Article History

Received: 3 November 2021

Accepted: 13 December 2021

First Online: 20 January 2022

Declarations

:

: The ethics committees of the Amsterdam UMC – Location VUmc and the Netherlands Brain Bank and the ethic committee of the University of California and Neurodegenerative Disease Brain Bank provided approval for the conduction of this work and all donors gave consent to participate in research.

: This manuscript was previously published as a pre-print on the medRxiv website; MS ID#: MEDRXIV/2021/265649.

: All donors gave consent for publication of results based on their data.

: Gil D. Rabinovici reports research support from Avid Radiopharmaceuticals, GE Healthcare, Eli Lilly, Life Molecular Imaging; Scientific advisory boards for Axon Neurosciences, Eiasi, Merck, Roche; Associate Editor for JAMA Neurology. Frederik Barkhof reports research support from GE Healthcare, Biogen, Novartis and TEVA; Scientific advisory boards for Roche, Biogen, Merck, Roche. Lundbeck and IXICO. Philip Scheltens serves/has served on the advisory boards of: Genentech, Novartis, Pfizer, Roche, Danone, Nutricia, Jansen AI, Baxter, and Lundbeck. He has been a speaker at symposia organized by Lundbeck, Lilly, Merz, Pfizer, Jansen AI, Danone, Novartis, Roche, and Genentech. He serves on the editorial board of Alzheimer’s Research & Therapy and Alzheimer Disease and Associated Disorders and is a member of the scientific advisory board of the EU Joint Programming Initiative and the French National Plan Alzheimer. The Alzheimer Center receives unrestricted funding from various sources through the VUmc Fonds. Dr. Scheltens receives no personal compensation for the activities mentioned above. Rik Ossenkoppele is an associate editor for Alzheimer’s Research & Therapy.